RBC Capital analysts provided their outlook on Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ahead of the upcoming Q4 earnings, expected to be released on Tuesday.
The company announced preliminary Q4/22 revenues of $28.4 million that were ahead of Street estimates. Management expects LUPKYNIS net revenue in the range of $120-140 million in 2023 (vs. Street’s estimate of $136.5 million).
The analysts expect the focus to remain on LUPKYNIS growth and ring-fencing opportunities around the dosing patent. The management team holds the belief that the new patent application ‘140 has the capability to offer extra patent coverage for LUPKYNIS until 2037.
The analyst reiterated their Outperform – Speculative Risk rating on the stock with a price target of $11.